Research Article
Prognostic Factors for COVID-19 Hospitalized Patients with Preexisting Type 2 Diabetes
Table 2
Univariate Cox proportional hazard regression analysis results
| Variables | HR | 95% CI | value |
| Age, y | 1.06 | 1.01 | 1.19 | 0.025 | Duration of diabetes, y | 1.08 | 1.01 | 1.14 | 0.017 | Disease severity | Nonsevere | 1 | | | | Severe | 1.16 | 0.22 | 5.98 | 0.86 | Critical | 7.05 | 1.52 | 32.7 | 0.013 | Cardiovascular and cerebrovascular diseases | 5.03 | 1.88 | 13.43 | 0.0013 |
| Neutrophil count (109/L) | <40 | 1.33 | 0.26 | 6.87 | 0.73 | 40–75 | 1 | | | | >75 | 4.21 | 1.37 | 12.94 | 0.012 |
| Aspartate aminotransferase, U/L | 13–35 | 1 | | | | >35 | 7.9 | 2.7 | 23.13 | 0.0008 |
| Serum amyloid A (SAA), mg/L | 1.01 | 1.006 | 1.02 | <0.0001 | Blood glucose, mmol/L | 1.15 | 1.05 | 1.26 | 0.0022 | Diabetes treatment | Oral medication plus insulin | 0.202 | 0.045 | 0.91 | 0.037 | Oral medication only | 0.063 | 0.014 | 0.28 | 0.0003 | Insulin only | 1 | | | |
| Antibiotics | Ganciclovir | 5.27 | 1.2 | 23.21 | 0.028 | Corticosteroid/glucocorticoid | 10.31 | 2.32 | 45.76 | 0.0022 |
|
|